Patients with extensive-stage SCLC typically undergo immunotherapy in combination with chemotherapy [11,12], while patients with NSCLC typically receive treatment options such as chemotherapy, immunotherapy, and targeted therapy drugs such as EGFR and anaplastic lymphoma kinase (ALK) inhibitors [13]. Here, ALK is linked to non-small cell lung carcinoma.